Evaluation of potential immune-related adverse events in mouse lung tissues after anti-PD1 or anti-PD1 nanocapsule treatment

Immune-releated adverse events is a common side effect in immune-checkpoint bloakade therapy like anti-PD1. Here, we performed RNA sequencing of lung tissues after treatment of anti-PD1 or anti-PD1 nanocapsules to evaluate their transcriptomic change related to adverse events. Our analysis has revelaed that nanocapsules which can target tumor tissue more effectively rather than accumulating in healthy tissues cause less transcriptomic change and can potentially prevent immune0related adverse events in lung tissues.